Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125429161 | 12542916 | 1 | I | 20160617 | 20160628 | 20160710 | 20160710 | EXP | GB-MHRA-TPP19481039C2243547YC1466155535305 | GB-TEVA-672861ACC | TEVA | 72.00 | YR | F | Y | 80.00000 | KG | 20160710 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125429161 | 12542916 | 1 | PS | ATORVASTATIN | ATORVASTATIN | 1 | U | U | 78773 | ||||||||||
| 125429161 | 12542916 | 2 | C | AMITRIPTYLINE HYDROCHLORIDE. | AMITRIPTYLINE HYDROCHLORIDE | 1 | 2 DOSAGE FORMS DAILY; AT NIGHT 2DF DAILY | 1246 | DF | 0 | 2 | DF | QD | ||||||
| 125429161 | 12542916 | 3 | C | AMOXICILLIN. | AMOXICILLIN | 1 | 3 DOSAGE FORMS DAILY; | 260.875 | DF | 0 | 1 | DF | TID | ||||||
| 125429161 | 12542916 | 4 | C | ASPIRIN. | ASPIRIN | 1 | 1 DOSAGE FORMS DAILY; EACH MORNING, 1 DF DAILY | 42 | DF | 0 | 1 | DF | TABLET | QD | |||||
| 125429161 | 12542916 | 5 | C | BENDROFLUMETHIAZIDE | BENDROFLUMETHIAZIDE | 1 | 1 DOSAGE FORMS DAILY; IN THE MORNING.1 DF DAILY | 623 | DF | 0 | 1 | DF | QD | ||||||
| 125429161 | 12542916 | 6 | C | CALCIUM CARBONATE. | CALCIUM CARBONATE | 1 | 2 DOSAGE FORMS DAILY; | 658 | DF | 0 | 1 | DF | BID | ||||||
| 125429161 | 12542916 | 7 | C | IBUPROFEN. | IBUPROFEN | 1 | Topical | APPLY 3-4 TIMES A DAY | 0 | ||||||||||
| 125429161 | 12542916 | 8 | C | LISINOPRIL. | LISINOPRIL | 1 | 1 DOSAGE FORMS DAILY; | 623 | DF | 0 | 1 | DF | QD | ||||||
| 125429161 | 12542916 | 9 | C | PIROXICAM. | PIROXICAM | 1 | Topical | APPLY AS DIRECTED | 0 | ||||||||||
| 125429161 | 12542916 | 10 | C | SEREVENT DISKUS | SALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 4 DOSAGE FORMS DAILY; | 2492 | DF | 0 | 2 | DF | BID | |||||
| 125429161 | 12542916 | 11 | C | VENTOLIN | ALBUTEROL SULFATE | 1 | Respiratory (inhalation) | 8 DOSAGE FORMS DAILY; AS REQUIRED. 8 DF DAILY | 4984 | DF | 0 | 2 | DF | QID |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125429161 | 12542916 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125429161 | 12542916 | Blood creatine phosphokinase increased | |
| 125429161 | 12542916 | Muscle atrophy | |
| 125429161 | 12542916 | Muscular weakness | |
| 125429161 | 12542916 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125429161 | 12542916 | 1 | 20141003 | 0 | ||
| 125429161 | 12542916 | 2 | 20141003 | 0 | ||
| 125429161 | 12542916 | 3 | 20160322 | 20160327 | 0 | |
| 125429161 | 12542916 | 4 | 20160506 | 0 | ||
| 125429161 | 12542916 | 5 | 20141003 | 0 | ||
| 125429161 | 12542916 | 6 | 20150724 | 0 | ||
| 125429161 | 12542916 | 7 | 20160603 | 20160604 | 0 | |
| 125429161 | 12542916 | 8 | 20141003 | 0 | ||
| 125429161 | 12542916 | 9 | 20160506 | 20160603 | 0 | |
| 125429161 | 12542916 | 10 | 20141003 | 0 | ||
| 125429161 | 12542916 | 11 | 20141003 | 0 |